Immunovant Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	902.11	713.97	635.37	376.53	493.82
Cash & Short-Term Investments	902.11	713.97	635.37	376.53	493.82
Cash Growth	26.35%	12.37%	68.74%	-23.75%	23.41%
Accounts Receivable	1.13	2.08	5.34	0.7	12.23
Other Current Assets	45.58	51.61	25.07	27.1	6.89
Total Current Assets	948.82	767.66	665.77	404.33	512.93
Net Property, Plant & Equipment	0.52	0.94	0.6	1.51	2.63
Other Long-Term Assets	7.68	7.62	-	-	-
Total Assets	957.01	776.22	666.37	405.84	515.56
Accounts Payable	7.54	17.66	7.16	1.35	18.63
Accrued Expenses	96.63	50.75	41.3	40.42	24.58
Current Portion of Leases	0.07	0.1	0.14	1.17	1.15
Other Current Liabilities	0.18	0.27	0.02	0.35	0.17
Total Current Liabilities	104.42	68.78	48.61	43.3	44.52
Long-Term Leases	-	-	-	0.05	1.22
Total Long-Term Liabilities	-	-	-	0.05	1.22
Total Liabilities	104.42	68.78	48.61	43.34	45.74
Common Stock	0.02	0.02	0.01	0.01	0.01
Additional Paid-in Capital	2,597	1,946	1,442	927.98	824.8
Accumulated Other Comprehensive Income	0.73	1.46	1.91	0.85	0.4
Retained Earnings	-1,745	-1,240	-825.68	-566.35	-355.39
Shareholders' Equity	852.59	707.45	617.76	362.49	469.83
Total Liabilities & Equity	957.01	776.22	666.37	405.84	515.56
Total Debt	0.07	0.1	0.14	1.22	2.36
Net Cash (Debt)	902.04	713.87	635.23	375.31	491.45
Net Cash Growth	26.36%	12.38%	69.25%	-23.63%	23.88%
Net Cash Per Share	4.95	4.71	4.60	3.05	4.48
Book Value	852.59	707.45	617.76	362.49	469.83
Book Value Per Share	4.67	4.67	4.47	2.95	4.28
Tangible Book Value	852.59	707.45	617.76	362.49	469.83
Tangible Book Value Per Share	4.67	4.67	4.47	2.95	4.28

SEC Filings: 10-K · 10-Q